TY - JOUR
T1 - Stress testing the Centiloid
T2 - Precision and variability of PET quantification of amyloid pathology
AU - Shekari, Mahnaz
AU - Vállez García, David
AU - Collij, Lyduine E.
AU - Altomare, Daniele
AU - Heeman, Fiona
AU - Pemberton, Hugh
AU - Roé Vellvé, Núria
AU - Bullich, Santiago
AU - Buckley, Christopher
AU - Stephens, Andrew
AU - Farrar, Gill
AU - Frisoni, Giovanni
AU - Klunk, William E.
AU - Barkhof, Frederik
AU - Gispert, Juan Domingo
AU - ADNI and the AMYPAD consortium
PY - 2024/8
Y1 - 2024/8
N2 - INTRODUCTION: Assessing the potential sources of bias and variability of the Centiloid (CL) scale is fundamental for its appropriate clinical application. METHODS: We included 533 participants from AMYloid imaging to Prevent Alzheimer's Disease (AMYPAD DPMS) and Alzheimer's Disease Neuroimaging Initiative (ADNI) cohorts. Thirty-two CL pipelines were created using different combinations of reference region (RR), RR and target types, and quantification spaces. Generalized estimating equations stratified by amyloid positivity were used to assess the impact of the quantification pipeline, radiotracer, age, brain atrophy, and harmonization status on CL. RESULTS: RR selection and RR type impact CL the most, particularly in amyloid-negative individuals. The standard CL pipeline with the whole cerebellum as RR is robust against brain atrophy and differences in image resolution, with 95% confidence intervals below ± 3.95 CL for amyloid beta positivity cutoffs (CL < 24). DISCUSSION: The standard CL pipeline is recommended for most scenarios. Confidence intervals should be considered when operationalizing CL cutoffs in clinical and research settings. Highlights: We developed a framework for evaluating Centiloid (CL) variability to different factors. Reference region selection and delineation had the highest impact on CL values. Whole cerebellum (WCB) and whole cerebellum plus brainstem (WCB+BSTM) as reference regions yielded consistent results across tracers. The standard CL pipeline is robust against atrophy and image resolution variation. Estimated within- and between-pipeline variability (95% confidence interval) in absolute CL units.
AB - INTRODUCTION: Assessing the potential sources of bias and variability of the Centiloid (CL) scale is fundamental for its appropriate clinical application. METHODS: We included 533 participants from AMYloid imaging to Prevent Alzheimer's Disease (AMYPAD DPMS) and Alzheimer's Disease Neuroimaging Initiative (ADNI) cohorts. Thirty-two CL pipelines were created using different combinations of reference region (RR), RR and target types, and quantification spaces. Generalized estimating equations stratified by amyloid positivity were used to assess the impact of the quantification pipeline, radiotracer, age, brain atrophy, and harmonization status on CL. RESULTS: RR selection and RR type impact CL the most, particularly in amyloid-negative individuals. The standard CL pipeline with the whole cerebellum as RR is robust against brain atrophy and differences in image resolution, with 95% confidence intervals below ± 3.95 CL for amyloid beta positivity cutoffs (CL < 24). DISCUSSION: The standard CL pipeline is recommended for most scenarios. Confidence intervals should be considered when operationalizing CL cutoffs in clinical and research settings. Highlights: We developed a framework for evaluating Centiloid (CL) variability to different factors. Reference region selection and delineation had the highest impact on CL values. Whole cerebellum (WCB) and whole cerebellum plus brainstem (WCB+BSTM) as reference regions yielded consistent results across tracers. The standard CL pipeline is robust against atrophy and image resolution variation. Estimated within- and between-pipeline variability (95% confidence interval) in absolute CL units.
KW - age
KW - Alzheimer's disease
KW - amyloid PET accuracy
KW - biomarker validation
KW - brain atrophy
KW - clinical applications
KW - clinical trials
KW - context of use
KW - diagnosis
KW - disease-modifying therapies
KW - image harmonization
KW - radiotracers
KW - white matter
U2 - 10.1002/alz.13883
DO - 10.1002/alz.13883
M3 - Article
C2 - 38961808
AN - SCOPUS:85197900292
SN - 1552-5260
VL - 20
SP - 5102
EP - 5113
JO - Alzheimer's and Dementia
JF - Alzheimer's and Dementia
IS - 8
ER -